Drug Trial Radar · NCT03726294
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
Last checked: Nov 19, 2026Latest source record: Apr 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Oct 16, 2018
Primary completion
Apr 24, 2020
Study completion Oct 25, 2021
Sponsor
- Lead sponsor
- NatureWise Biotech & Medicals CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8. The objectives of this study are to determine the safety profile of NBM-BMX, including identification of dose limiting toxicity (DLT) and maximum tolerated dose (MTD), and to determine the Recommended Phase 2 Dose (RP2D).
Conditions
- Malignant Neoplasm
Interventions
NBM-BMX softgel capsulesDrug
Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days
- Maximum tolerated dose (MTD) of NBM-BMX [Safety and Tolerability]Time frame: up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.